P E Greenberg

Summary

Affiliation: Analysis Group
Country: USA

Publications

  1. ncbi Assessing the economic impact of psychiatric disorders: where to begin?
    P E Greenberg
    Analysis Group Economics, One Brattle Square, Fifth Floor, Cambridge, MA 02138, USA
    Expert Opin Pharmacother 2:641-52. 2001
  2. ncbi The economic burden of depression in the US: societal and patient perspectives
    Paul E Greenberg
    Analysis Group, Inc, 111 Huntington Ave, 10th Floor, Boston, MA 02199, USA
    Expert Opin Pharmacother 6:369-76. 2005
  3. ncbi Economic implications of treatment-resistant depression among employees
    Paul Greenberg
    Analysis Group Inc, Boston, Massachusetts 02199, USA
    Pharmacoeconomics 22:363-73. 2004
  4. ncbi The economic burden of depression in the United States: how did it change between 1990 and 2000?
    Paul E Greenberg
    Analysis Group, Inc, Boston, MA 02199, USA
    J Clin Psychiatry 64:1465-75. 2003
  5. ncbi The economic burden of depression with painful symptoms
    Paul E Greenberg
    Analysis Group Economics, Inc, Boston, MA 02199, USA
    J Clin Psychiatry 64:17-23. 2003
  6. ncbi The effects of chronic medical conditions on work loss and work cutback
    R C Kessler
    Department of Health Care Policy, Harvard Medical School, 180 Longwood Avenue, Boston, MA, USA
    J Occup Environ Med 43:218-25. 2001
  7. ncbi Economic burden of pneumonia in an employed population
    H G Birnbaum
    Analysis Group Economics, One Brattle Square, Fifth Floor, Cambridge, MA 02138, USA
    Arch Intern Med 161:2725-31. 2001
  8. ncbi Workplace performance effects from chronic depression and its treatment
    E R Berndt
    MIT Sloan School of Management, Cambridge, MA 02142, USA
    J Health Econ 17:511-35. 1998
  9. ncbi The risks and costs of multiple-generic substitution of topiramate
    M S Duh
    Analysis Group, Inc, Boston, MA 02199, USA
    Neurology 72:2122-9. 2009
  10. ncbi Impact of illness and its treatment on workplace costs: regulatory and measurement issues
    P E Greenberg
    Analysis Group/Economics, One Brattle Square, Fifth Floor, Cambridge, MA 02138, USA
    J Occup Environ Med 43:56-63. 2001

Detail Information

Publications22

  1. ncbi Assessing the economic impact of psychiatric disorders: where to begin?
    P E Greenberg
    Analysis Group Economics, One Brattle Square, Fifth Floor, Cambridge, MA 02138, USA
    Expert Opin Pharmacother 2:641-52. 2001
    ..These categories present a starting point for analysing the pharmacoeconomic consequences of psychiatric disorders and underlie an expert opinion in this context..
  2. ncbi The economic burden of depression in the US: societal and patient perspectives
    Paul E Greenberg
    Analysis Group, Inc, 111 Huntington Ave, 10th Floor, Boston, MA 02199, USA
    Expert Opin Pharmacother 6:369-76. 2005
    ..Future investigation is likely to focus on the relationship between depression and comorbid conditions, the role of caregiver burdens, and the economic differences in life outcomes...
  3. ncbi Economic implications of treatment-resistant depression among employees
    Paul Greenberg
    Analysis Group Inc, Boston, Massachusetts 02199, USA
    Pharmacoeconomics 22:363-73. 2004
    ..Given the prevalence of the disorder, it is understandable that MDDs are responsible for a significant amount of both direct and indirect healthcare costs...
  4. ncbi The economic burden of depression in the United States: how did it change between 1990 and 2000?
    Paul E Greenberg
    Analysis Group, Inc, Boston, MA 02199, USA
    J Clin Psychiatry 64:1465-75. 2003
    ..9 billion dollars using revised prevalence data and a refined workplace cost estimation approach. The objective of the current report is to provide a 10-year update of these estimates using the same methodological framework...
  5. ncbi The economic burden of depression with painful symptoms
    Paul E Greenberg
    Analysis Group Economics, Inc, Boston, MA 02199, USA
    J Clin Psychiatry 64:17-23. 2003
    ..However, more research is needed to assess the comprehensive economic impact that depression with painful physical symptoms can have on society...
  6. ncbi The effects of chronic medical conditions on work loss and work cutback
    R C Kessler
    Department of Health Care Policy, Harvard Medical School, 180 Longwood Avenue, Boston, MA, USA
    J Occup Environ Med 43:218-25. 2001
    ....
  7. ncbi Economic burden of pneumonia in an employed population
    H G Birnbaum
    Analysis Group Economics, One Brattle Square, Fifth Floor, Cambridge, MA 02138, USA
    Arch Intern Med 161:2725-31. 2001
    ..To estimate the overall economic burden of pneumonia from an employer perspective...
  8. ncbi Workplace performance effects from chronic depression and its treatment
    E R Berndt
    MIT Sloan School of Management, Cambridge, MA 02142, USA
    J Health Econ 17:511-35. 1998
    ..Those patients having the greatest work improvement are those with both relatively low baseline work performance and the least severity of baseline depression...
  9. ncbi The risks and costs of multiple-generic substitution of topiramate
    M S Duh
    Analysis Group, Inc, Boston, MA 02199, USA
    Neurology 72:2122-9. 2009
    ..To investigate clinical and economic consequences following generic substitution of one vs multiple generics of topiramate (Topamax; Ortho-McNeil Neurologics, Titusville, NJ)...
  10. ncbi Impact of illness and its treatment on workplace costs: regulatory and measurement issues
    P E Greenberg
    Analysis Group/Economics, One Brattle Square, Fifth Floor, Cambridge, MA 02138, USA
    J Occup Environ Med 43:56-63. 2001
    ..This discussion highlights the possible difficulties faced by the FDA in reviewing productivity-based promotional claims. Finally, we suggest possible strategies for furthering this field of investigation...
  11. ncbi Management of anaemia: a critical and systematic review of the cost effectiveness of erythropoiesis-stimulating agents
    Mei Sheng Duh
    Analysis Group, Inc, Boston, Massachusetts 02199, USA
    Pharmacoeconomics 26:99-120. 2008
    ....
  12. ncbi Considering the costs of bipolar depression
    Ronald C Kessler
    Harvard Medical School, USA
    Behav Healthc 27:45-7. 2007
  13. ncbi Estimated costs of prescription opioid analgesic abuse in the United States in 2001: a societal perspective
    Howard G Birnbaum
    Analysis Group, Inc, Boston, MA 02199, USA
    Clin J Pain 22:667-76. 2006
    ..This study estimates the costs to society of prescription opioid analgesic (RxO) abuse in the United States...
  14. ncbi Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000
    Howard G Birnbaum
    Analysis Group, Inc, Boston, MA 02199, USA
    Curr Med Res Opin 21:195-206. 2005
    ..The objective of this study is to provide a comprehensive estimate of the cost of ADHD by consider ing the healthcare and work loss costs of persons with ADHD, as well as those costs imposed on their family members...
  15. ncbi The economics of women and depression: an employer's perspective
    Howard G Birnbaum
    111 Huntington Avenue, Tenth Floor, Boston, MA 02199, USA
    J Affect Disord 74:15-22. 2003
    ..This analysis focuses on the direct and indirect cost to employers of female compared to male employees treated for depression, and their service utilization patterns...
  16. ncbi Depression and fibromyalgia: treatment and cost when diagnosed separately or concurrently
    Rebecca L Robinson
    Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Rheumatol 31:1621-9. 2004
    ..Both syndromes share common symptoms and impose significant economic burdens. This study compared claims for treatment and costs of FM plus depression with those for FM or depression alone...
  17. ncbi Direct and indirect costs of asthma to an employer
    Howard G Birnbaum
    Analysis Group/Economics, Cambridge, MA 02138, USA
    J Allergy Clin Immunol 109:264-70. 2002
    ..CONCLUSION: Failure to account fully for the broader consequences of asthma in terms of indirect and comorbid treatment costs would result in a significant underassessment of the cost of asthma to an employer...
  18. ncbi Economic burden of respiratory infections in an employed population
    Howard G Birnbaum
    Analysis Group Economics, Boston, MA 02199, USA
    Chest 122:603-11. 2002
    ..While respiratory infections are a leading cause of morbidity, there is little information on the costs of medically treating these conditions, or on their workplace impact...
  19. ncbi Identification of a claims data "signature" and economic consequences for treatment-resistant depression
    Patricia K Corey-Lisle
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Psychiatry 63:717-26. 2002
    ....
  20. ncbi Economic cost and epidemiological characteristics of patients with fibromyalgia claims
    Rebecca L Robinson
    Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Rheumatol 30:1318-25. 2003
    ..We investigated the total costs of FM in an employer population...
  21. ncbi Economic consequences of not recognizing bipolar disorder patients: a cross-sectional descriptive analysis
    Howard G Birnbaum
    Analysis Group, Inc, 111 Huntington Avenue, Boston, MA 02466, USA
    J Clin Psychiatry 64:1201-9. 2003
    ..This retrospective study compared treatment patterns and costs for patients with recognized and unrecognized bipolar disorder with those of depressed patients without a bipolar disorder claim...
  22. ncbi Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication
    Kathleen R Merikangas
    Intramural Research Program, Section on Developmental Genetic Epidemiology, National Institute of Mental Health, Bethesda, MD 20892, USA
    Arch Gen Psychiatry 64:543-52. 2007
    ..There is growing recognition that bipolar disorder (BPD) has a spectrum of expression that is substantially more common than the 1% BP-I prevalence traditionally found in population surveys...